INTRODUCTION {#s1}
============

Retinol dehydrogenase 12 (*RDH12*) is a member of a short-chain dehydrogenase/reductase superfamily highly expressed in the photoreceptors ([@MCS004754SCOC27]; [@MCS004754SCOC24]). RDH12 and RDH8, another enzyme from the same family, convert all-*trans*-retinal to all-*trans*-retinol, which is a crucial step in the vitamin A cycle, also called the visual cycle ([@MCS004754SCOC18]; [@MCS004754SCOC6]; [@MCS004754SCOC34]). RDH8, localized in the photoreceptor outer segments, converts most of the all-*trans*-retinal necessary for the visual cycle, whereas RDH12, localized in the inner segments, is crucial for the reduction of all-*trans*-retinal in the inner segments preventing the buildup of toxic aldehydes. Accumulation of these aldehydes is thought to be the major cause of photoreceptor cell loss, as mutations in *RDH12* and not *RDH8* have been associated with disease ([@MCS004754SCOC41]; [@MCS004754SCOC28]; [@MCS004754SCOC29]; [@MCS004754SCOC9]).

Mutations in *RDH12* were first discovered to cause a recessive form of Leber congenital amaurosis (LCA), which is an early-onset retinal degeneration ([@MCS004754SCOC39]; [@MCS004754SCOC20]; [@MCS004754SCOC35]). *RDH12*-associated disease is thought to account for up to 4% of LCA cases ([@MCS004754SCOC35]). Subsequently, mutations in *RDH12* have been found in patients with autosomal recessive (AR) retinitis pigmentosa (RP) as well as cone-rod dystrophies (CORDs) ([@MCS004754SCOC20]; [@MCS004754SCOC8]; [@MCS004754SCOC19]). Characteristics of disease caused by recessive biallelic mutations in *RDH12* include early-onset progressive degeneration of both rods and cones with severely reduced or extinguished responses on electroretinogram (ERG) ([@MCS004754SCOC38]). A dominant form of *RDH12* disease has also been reported ([@MCS004754SCOC16]).

Here we present eleven cases of recessive *RDH12*-associated disease with variable age of onset and severity as well as widening the phenotypic spectrum of *RDH12*-associated disease to include macular dystrophy. Using whole-exome sequencing (WES) and next-generation sequencing (NGS) panel testing specific for inherited retinal degeneration (IRD) genes ([@MCS004754SCOC10]) versus sequencing based on rigid phenotypes allowed the diagnosis of patients with milder retinal degeneration phenotypes less commonly associated with *RDH12* mutations. We also report four novel variants expanding the catalog of causal variants in *RDH12*.

RESULTS {#s2}
=======

Genomic Analysis {#s2a}
----------------

Analysis of 11 patients with retinal degeneration by WES and NGS panel testing identified 16 missense mutations in *RDH12*, of which four missense variants were novel ([Tables 1](#MCS004754SCOTB1){ref-type="table"} and [2](#MCS004754SCOTB2){ref-type="table"}). When possible, segregation analysis was performed with available family members, otherwise variants were confirmed to be in *trans* either by NGS paired-end reads or cloning of a large fragment followed by Sanger sequencing ([Supplemental Fig. S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1)). Mutations found in the present study span the entire length of the protein, residing in regions vital to the underlying function of the RDH12 enzyme, including nucleotide-binding regions and catalytic regions ([Fig. 1](#MCS004754SCOF1){ref-type="fig"}A). The novel missense variants---c.215G \> A (p.Asp72Gly) (exon 3) c.362T \> C (p.Ile121Thr), c.440A \> C (p.Asn147Thr) (exon4), and c.697G \> A (p.Val233Ille) (exon 6)---all reside within the RDH12 catalytic domain ([Fig. 1](#MCS004754SCOF1){ref-type="fig"}A). They were predicted to be damaging according to in silico predictions and were either extremely rare (MAF \< 0.001) or not present in gnomAD ([Tables 1](#MCS004754SCOTB1){ref-type="table"} and [2](#MCS004754SCOTB2){ref-type="table"}; [@MCS004754SCOC22]) as well as their respective amino acid positions being highly conserved ([Fig. 1](#MCS004754SCOF1){ref-type="fig"}B).

![RDH12 protein and alignment. (*A*) Mutations identified in this study listed with gene and protein structure. Novel mutations appear in red; variants that have been functionally validated previously are in bold. The *RDH12* gene (*top*) with coding exons is shaded in blue. Protein (*below*) is shown with dashed lines demarcating exon boundaries with amino acids numbered. NAD(P)H binding is shown in the dark green square (46--52 aa); the area in green shows the short-chain dehydrogenase/reductase homology (40--243) with active site (175 aa) and proton acceptor (200 aa) in dark green. Proposed signal peptide shown in yellow (1--27 aa). Domains and motifs defined by <https://www.ebi.ac.uk/interpro/protein/Q96NR8> and <http://pfam.xfam.org/protein/Q96NR8>. (*B*) The protein alignment of the substituted amino acids resulting from novel mutations. (*B*, From [blast.ncbi.nlm.nih.gov/](blast.ncbi.nlm.nih.gov/).)](MCS004754Sco_F1){#MCS004754SCOF1}

###### 

RDH12 variants in cohort

  Sample ID          Diagnosis         cDNA change       Protein change    CADD score    ACMG                 Segregation                                                                                                                                    GnomAD        Published
  ------------------ ----------------- ----------------- ----------------- ------------- -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------- --------------------
  **OGI519-1068**    MD                c.701G \> A       p.Arg234His       12.04         LP                   Determined by paired-end NGS reads ([Supplemental Fig. S1a](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))   0.000099      [@MCS004754SCOC41]
  c.844T \> G        p.Phe282Val       32.0              LP                0.000004      [@MCS004754SCOC10]                                                                                                                                                                
  **OGI3079-4672**   MD                c.185G \> T       p.Arg62Leu        34            LP                   Determined by cloning and Sanger ([Supplemental Fig. S1b](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))     0.0001747     [@MCS004754SCOC13]
  c.619A \> G        p.Asn207Asp       25.8              LP                0.000007964   [@MCS004754SCOC26]                                                                                                                                                                
  **OGI2933-4518**   MD                **c.440A \> C**   **p.Asn147Thr**   28.1          P                    Determined by cloning and Sanger ([Supplemental Fig. S1c](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))     0.000003977   This study
  c.701G \> A        p.Arg234His       12.04             LP                0.000099      [@MCS004754SCOC41]                                                                                                                                                                
  **OGI3076-4666**   CORD              c.619A \> G       p.Asn207Asp       25.8          LP                   Paternal                                                                                                                                       0.000007964   [@MCS004754SCOC26]
  **c.697G \> A**    **p.Val233Ile**   20.5              P                 Maternal      0.0                  This study                                                                                                                                                   
  **OGI2356-3915**   EORD              c.194G \> A       p.Arg65Gln        32.0          VUS                  N/A                                                                                                                                            0.00001768    [@MCS004754SCOC41]
  c.506G \> A        p.Arg169Gln       27.4              LP                0.00001193    [@MCS004754SCOC26]                                                                                                                                                                
  **OGI1611-2841**   RP                c.146C \> T       p.Thr49Met        28.0          P                    Hom                                                                                                                                            0.00001768    [@MCS004754SCOC20]
  **OGI3077-4669**   EORD              c.146C \> T       p.Thr49Met        28.0          P                    Hom (unaffected brother het)                                                                                                                   0.00001768    [@MCS004754SCOC20]
  **OGI1662-2892**   EORD              c.164C \> T       p.Thr55Met        28.0          LP                   Determined by paired-end NGS reads ([Supplemental Fig. S1d](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))   0.00002386    [@MCS004754SCOC41]
  c.184C \> T        p.Arg62\*         35.0              P                 0.00005659    [@MCS004754SCOC20]                                                                                                                                                                
  **OGI1613-2843**   RP                **c.215A \> G**   **p.Asp72Gly**    28.0          LP                   Determined by cloning and Sanger ([Supplemental Fig. S1e](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))     0.0           This study
  c.524C \> T        p.Ser175Leu       26.0              LP                0.000045      [@MCS004754SCOC11]                                                                                                                                                                
  **OGI1610-2840**   RP                **c.362T \> C**   **p.Ile121Thr**   26            LP                   Determined by cloning and Sanger ([Supplemental Fig. S1f](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1))     0.0           This study
  c.883C \> T        p.Arg295\*        39                LP                0.000018      [@MCS004754SCOC41]                                                                                                                                                                
  **OGI1242-2406**   CORD              c.295C \> A       p.Leu99Ile        23.8          P                    Hom                                                                                                                                            0.00006       [@MCS004754SCOC35]

**Bold** entries are novel variants found in this study.

\(MD\) Macular dystrophy, (CORD) cone-rod dystrophy, (EORD) early-onset severe retinal dystrophy, (RP) retinitis pigmentosa, (CADD) combined annotation dependent depletion, (ACMG) American College of Medical Genetics and Genomics with variant classifications of (P) pathogenic, (LP) likely pathogenic, or (VUS) variant of unknown significance, (NGS) next-generation sequencing, (gnomAD) Genome Aggregation Database.

###### 

In silico analysis of novel variants

                             Amino acid change   Conservation                                                                         
  -------------------------- ------------------- ---------------------- ------------------------- ----------------- ----------------- -----------------
  c.215A \> G p.(Asp72Gly)   Deleterious 0.03    Disease causing 1.00   Possibly damaging 0.948   Conserved 5.65    Conserved 0.999   Conserved 4.839
  c.362T \> C p.Ile121Thr    Deleterious 0       Disease causing 1.00   Probably damaging 0.979   Conserved 6.04    Conserved 1       Conserved 5.252
  c.440A \> C p.Asn147Thr    Deleterious 0       Disease causing 1.00   Probably damaging 1.00    Conserved 6.040   Conserved 1       Conserved 5.253
  c.697G \> A p.Val233Ile    Deleterious 0       Disease causing 1.00   Probably damaging 0.999   Conserved 5.74    Conserved 1       Conserved 6.212

Prediction of pathogenicity of novel variants in RDH12.

(SIFT) Sorting Intolerant from Tolerant, (PolyPhen-2) Polymorphism Phenotyping version 2, (GERP) genomic evolutionary rate profiling.

All of the reported subjects carried rare variants in other IRD genes; however, these were not considered as causal as they were either single alleles in autosomal recessive genes or too common to be causative of autosomal dominant forms of IRDs ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1)). Of interest, two subjects were identified to have one heterozygous variant in the gene *ABCA4*. For one case, OGI3076-4666, this finding initially led to a diagnosis of Stargardt disease. After NGS panel sequencing, no other potentially causal *ABCA4* variants were found for this subject, and although this gene is enriched with deep intronic noncoding mutations ([@MCS004754SCOC5]; [@MCS004754SCOC37]; [@MCS004754SCOC2]), the clinical and genetic findings pointed to compound heterozygous *RDH12* mutations c.619A \> G (p.Asn207Asp) and c.697G \> A (p.Val233Ile) as the likely cause of disease. Similarly, we did not detect a second causal *ABCA4* allele in subject OGI3077-4669 or likely pathogenic mutations in other IRD genes ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1)).

Clinical Presentations {#s2b}
----------------------

Eleven subjects were seen at the Retina or Inherited Retinal Disorders Services at Massachusetts Eye and Ear between 1979 and 2019, with follow-up data available for seven individuals ([Table 3](#MCS004754SCOTB3){ref-type="table"}). Age at reported symptom onset ranged from 2 to 26 yr (mean = 9.5) with decreased central vision and nyctalopia as common initial complaints. All subjects had decreased visual acuity at initial presentation, and progressive vision loss to hand motion or worse was observed in cases when follow-up was possible over many decades. Goldmann perimetry was performed in nine individuals with findings ranging from isolated central scotomas to retention of central sensitivity only. Full-field ERG findings showed non-detectable rod and severely reduced cone responses in most patients ([Table 3](#MCS004754SCOTB3){ref-type="table"}).

###### 

Clinical summaries

  ID (sex)              Clinical diagnosis                     Onset age (yr); symptoms at onset            Visual acuity                                                  Goldmann perimetry                                                                         Fundus                                                                                                                                                                                Auto fluorescence                                                                                              OCT                                                                                                     ERG^c^
  --------------------- -------------------------------------- -------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  OGI519-1068 (F)       Macular dystrophy                      6; ↓ central vision                          8y: OD: 20/60; OS: 20/60; 14y: OD: 20/125; OS: 20/100          8y: 5° central scotoma (I4e); 14y: 15° central scotoma (I4e)                               8 yr and 14 yr: Ring of parafoveal atrophy, periphery normal                                                                                                                          14 yr: Parafoveal ring of hypoAF with hyperAF rim; similar to age 10                                           14 yr: Diffuse PR loss, parafoveal RPE atrophy; similar to age 10                                       8 yr: Normal rod and cone responses
  OGI3079-4672 (M)      Macular dystrophy                      17; ↓ central vision                         33 yr: OD: 20/80; OS: 20/80                                    Central scotomas (5° V4e; 15°I2e and I4e)                                                  Central macular atrophy; few patches of paravenous atrophy                                                                                                                            Central macular hypoAF with hyperAF rim; few small paravenous hyperAF rings                                    Bare foveal outer retinal structures with diffuse central PR and RPE loss elsewhere in central macula   Normal rod and cone responses
  OGI2933-4518^a^ (F)   Macular dystrophy                      Childhood; ↓ central vision                  29 yr: OU: 20/160; 34y: OD:20/100; OS: 20/150                  N/A                                                                                        29 yr: Extensive macular atrophy with peripapillary sparing, peripheral atrophy including perivascular patches                                                                        N/A                                                                                                            N/A                                                                                                     N/A
  OGI3076-4666 (M)      Cone-rod dystrophy                     8; photophobia and ↓ color vision            13 yr: OD:20/100; OS:20/70                                     N/A                                                                                        Atrophy in macula and posterior pole atrophy with peripapillary sparing, nummular peripheral atrophy, attenuated vessels                                                              Macular hypoAF with peripapillary sparing; diffuse peripheral zones of scalloped hypoAF with hyperAF outline   Diffuse outer retinal loss with focal subfoveal EZ and intact peripapillary outer retina                Multifocal ERG OD: Diffuse flattening with small peak centrally
  OGI2356-3915 (F)      Early-onset severe retinal dystrophy   3; nyctalopia and ↓ central vision           7 yr (sc): OD 20/50; OS 20/100; 11 yr: OD: 20/60; OS: 20/100   10 yr: Paracentral and mid-peripheral scotomas                                             10 yr: Atrophy in macula and posterior pole, peripapillary sparing, nummular peripheral atrophy, attenuated vessels                                                                   10 yr: Macular hypoAF with peripapillary sparing; peripheral hypoAF with hyperAF rim, perivascular hyperAF     10 yr: Diffuse outer retinal loss centrally with intact peripapillary outer retina                      7 yr, OD only: Rod amplitude ∼35% of normal; 30 Hz cone flicker ∼5 mcV
  OGI1611-2841 (M)      Retinitis pigmentosa                   6; ↓ night, central, and peripheral vision   26 yr: OD: 20/100; OS: 20/80; 48 yr^b^: OD: LP; OS: LP         26 yr: Generalized constriction (III4e ∼40°, V4e ∼80°)                                     26 yr: Macular atrophy and hyperpigmentation, peripheral bone spicules, attenuated vessels                                                                                            48 yr: Confluent hypoAF throughout macula and posterior pole; patchy hypoAF in periphery                       48 yr: Diffuse loss of PR and RPE                                                                       26 yr: Rod response ND; 30 Hz cone flicker ∼1.0 mcV
  OGI3077-4669 (M)      Early-onset severe retinal dystrophy   2; nyctalopia                                6 yr: OD:20/50; OS:20/50; 29 yr: OD:20/100; OS:20/200          6 yr: Midperipheral scotomas; 29 yr: Severe constriction (V4e \< 10°; peripheral island)   6 yr: Macular granularity, peripheral bone spicules; attenuated vessels; 29 yr: atrophy throughout posterior pole with pigment clumps; peripheral bone spicules; attenuated vessels   29 yr: Confluent macular hypoAF extending into midperiphery                                                    29 yr: Diffuse loss of photoreceptors and RPE; multiple focal pseudo-colobomas; choroidal atrophy       7 yr: Rod response ND; 30 Hz cone flicker ∼ 1.0 mcV
  OGI1662-2892 (M)      Early-onset severe retinal dystrophy   3; ↓ central vision                          6 yr:^b^ OD: 20/80; OS: 20/80                                  Mild constriction (I4e 20°, V4e full)                                                      Macular atrophy, peripheral bone spicules, attenuated vessels                                                                                                                         N/A                                                                                                            N/A                                                                                                     Rod response ND; 30 Hz cone flicker \< 5 mcV
  OGI1613-2843 (F)      Retinitis pigmentosa                   26; nyctalopia                               33 yr : OD 20/60; OS 20/80; 55 yr: OD: HM; OS: HM              44 yr: Severe constriction (V4e \< 5°)                                                     Macular atrophy with peripapillary sparing; peripheral bone spicules and attenuated vessels                                                                                           N/A                                                                                                            N/A                                                                                                     44 yr: Rod response ND; 30 Hz cone flicker \< 1 mcV
  OGI1610-2840 (F)      Retinitis pigmentosa                   9; nyctalopia & ↓ central vision             65 yr: OD: CF, OS: CF                                          Limited peripheral III4e sensitivity; near-full V4e                                        Macular atrophy, peripheral bone spicules, attenuated vessels                                                                                                                         N/A                                                                                                            N/A                                                                                                     Rod response ND; 30 Hz cone flicker \< 5.0 mcV
  OGI1242-2406 (F)      Cone-rod dystrophy                     Childhood; ↓ central vision OS               31 yr: OS: 20/125, OD: 20/125                                  Central and midperipheral scotomas                                                         Excavated macular atrophy; peripheral atrophy and bone spicules; attenuated vessels                                                                                                   Confluent hypoAF throughout macula and posterior pole; peripapillary sparing; patchy peripheral hypoAF         Central staphyloma with absent PR and RPE                                                               Rod response ∼20% of normal; 30 Hz cone flicker \<5.0 mcV

Imaging and testing correspond to age from most recent visual acuity reported unless otherwise noted.

(AF) Autofluorescence, (CF) count fingers, (ERG) electroretinogram, (EZ) ellipsoid zone, (HM) hand motion, (mcV) microvolt, (ND) nondetectable, (PR) photoreceptor, (RP) retinitis pigmentosa, (RPE) retinal pigment epithelium, (sc) without correction.

^a^Patient has an affected sibling not represented in this cohort.

^b^Nystagmus was noted at time of exam.

^c^Full-field unless indicated; bandpass filtering and computer averaging of 30 Hz responses performed.

Two individuals with normal full-field ERGs, OGI519-1068 and OGI3079-4672, were notable for macula-predominant disease based on functional and anatomic data ([Table 3](#MCS004754SCOTB3){ref-type="table"}; [Fig. 2](#MCS004754SCOF2){ref-type="fig"}A--F). One (OGI519-1068) noticed blurry central vision at age 6 and demonstrated macula-only disease on retinal imaging between ages 8 and 14 ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}A--C) with visual fields notable only for central scotomas and normal full-field ERG ([Table 3](#MCS004754SCOTB3){ref-type="table"}). OGI3079-4672, who first noticed decreased central vision at age 17, still maintained 20/80 visual acuity at age 33 with full visual fields beyond central scotomas and a normal ERG ([Table 3](#MCS004754SCOTB3){ref-type="table"}; [Fig. 2](#MCS004754SCOF2){ref-type="fig"}D--F). Both patients carried diagnoses of macular dystrophy and presented with significantly milder phenotype than reported cases of *RDH12*-associated disease.

![Clinical phenotypes of RDH12-associated patients. Widefield fundus photography, fundus autofluorescence imaging, and optical coherence tomography to demonstrate degree of retinal dystrophy in patients. (*A*--*C*) OGI519-1068, age 14; (*D*--*F*) OGI3079-4672, age 33; (*G*--*I*) OGI3076-4666, age 14; (*J*--*L*) OGI2356-3915, age 11; (*M*--*O*) OGI1242-2406, age 31; (*P*--*R*) OGI3077-4669, age 29.](MCS004754Sco_F2){#MCS004754SCOF2}

Fundus findings in our 11 patients ranged from isolated macular atrophy ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}A--C) to widespread atrophy throughout the posterior pole and peripheral retina ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}P,Q). In individuals with predominantly macula-involving disease, a bull\'s-eye pattern of parafoveal atrophy was seen with a triangular or torpedo-like shape pointing toward the temporal macula ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}B,E,H). Five patients with macula-predominant disease had peripapillary sparing of the outer retina clinically and on imaging (OGI519-1068, OGI3079-4672, OGI2933-4518 and OGI3076-4666**,** OGI1242-2406, [Table 3](#MCS004754SCOTB3){ref-type="table"}; [Fig. 2](#MCS004754SCOF2){ref-type="fig"}). In more severe disease, the macular atrophy acquired a more excavated appearance (OGI1242-2406 and OGI3077-4669, [Fig. 2](#MCS004754SCOF2){ref-type="fig"}). The majority of patients in this cohort also had peripheral atrophy ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}H,K,N,Q). Widefield fundus autofluorescence was notable for hyperfluorescent outlines around the macula, in nummular areas of atrophy along vessels, and in the periphery ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}, middle panel). Optical coherence tomography (OCT) demonstrated outer retinal atrophy as well as pseudocolobomatous lesions as previously noted ([Fig. 2](#MCS004754SCOF2){ref-type="fig"}, right panel; [@MCS004754SCOC3]).

DISCUSSION {#s3}
==========

Here, we report 11 subjects with biallelic mutations in *RDH12* that were diagnosed with retinal disease of varying severity including two subjects with a milder phenotype than previously reported. Two individuals were diagnosed with *RDH12*-related maculopathy, which has not been described previously to be associated with this gene. We identified 15 causal variants in this study, four of which were not previously reported---c.215A \> G (p.Asp72Gly), c.362T \> C (p.Ile121Thr), c.440A \> C (p.Asn147Thr), and c.697G \> A (p.Val233Ile). These novel mutations were located within regions previously shown to be critical to the enzymatic function of the RDH12 enzyme using functional studies ([@MCS004754SCOC41]; [@MCS004754SCOC40]). Although variants in other IRD genes have been identified, they were not determined to be the primary cause for disease either because of lack of an additional recessive allele in the same gene or dominant variants that were too common in the population genetic databases (gnomAD) ([@MCS004754SCOC22]) to be causal. We cannot rule out that these variants may be acting as modifiers, especially those that may act within the same pathway as *RDH12*.

*RDH12* mutations are associated with well-characterized retinal phenotypes developing in early childhood ([@MCS004754SCOC38]; [@MCS004754SCOC26]; [@MCS004754SCOC13]). Indeed, the majority of this cohort demonstrated severe early-onset disease and also exhibited the previously reported characteristic retinal features. Of the patients with available images, five demonstrated well-demarcated peripapillary sparing of the outer retina and two had diffuse atrophy ([@MCS004754SCOC17]). Other previously reported features included pseudocolobomatous changes on OCT ([@MCS004754SCOC3]) as well as "watercolor" hyperautofluorescence tracking along vessels ([@MCS004754SCOC13]).

Recent studies have reported later onset of *RDH12*-associated disease coinciding with milder phenotypes in patients diagnosed with arRP; however, decreased full-field ERG recordings and peripheral deterioration of the retina was noted ([@MCS004754SCOC13]; [@MCS004754SCOC45]). Several cases in this cohort, however, suggest the potential for milder *RDH12*-associated disease. Three of the 11 patients carried diagnoses of macular dystrophy, and of these, two had disease that was essentially limited to the macula. Although both of these subjects had reduced visual acuity, the macular focus of disease was confirmed by visual fields, normal full-field ERG recordings, and retinal imaging, thus demonstrating a much milder phenotype than that seen in other individuals in this study or reported elsewhere ([@MCS004754SCOC20]; [@MCS004754SCOC35]; [@MCS004754SCOC41]; [@MCS004754SCOC38]; [@MCS004754SCOC40]; [@MCS004754SCOC26]). Although Xin and colleagues reported a patient with macular findings and hyperautofluorescence along the vessels, the reported patient had reduced cone response amplitudes ([@MCS004754SCOC43]). Although one of the two individuals here was an adolescent at the time of last evaluation (OGI519-1068) and thus has an uncertain prognosis, the other (OGI3079-4672) was 33 years old, thus suggesting the possibility of sustained milder disease. Although our study is limited by being retrospective, with follow-up spread out over 40 years (1979--2019) with concomitant heterogeneity of clinical evaluation and available imaging data, overall our findings contribute to clinical understanding of *RDH12*-associated disease.

Of the four novel variants identified in this study, one, c.697G \> A, p.(Val233Ile), occurred at a mutational hotspot where c.697G \> C p.(Val233Leu), c.697G \> T p.(Val233Phe), c.698T \> A p.(Val233Asp), and a frameshift c.698insinsGT p.(Val233ValfsX45) have been reported to cause severe retinal disease ([@MCS004754SCOC11]; [@MCS004754SCOC26]; [@MCS004754SCOC25]; [@MCS004754SCOC42]; [@MCS004754SCOC21]). The variant in this study, c.697G \> A (p.Val233Ile), has been designated as causal in combination with c.619A \> G (p.Asn207Asp) in a subject with macular dystrophy (OGI3076-4666), further adding to the heterogeneity in this region.

We have reclassified c.701G \> A (p.Arg234His) as likely pathogenic in consideration of functional studies that demonstrated the mutation resulted in decreased expression and significantly reduced catalytic activity compared to wild-type RDH12 ([@MCS004754SCOC41]). This variant most likely results in a hypomorphic allele, which in combination with other missense mutations (p.Phe282Val in OGI519-1068 and p.Asn147Thr in OGI2933-4518), was determined to be causal in both patients ([Tables 1](#MCS004754SCOTB1){ref-type="table"} and [2](#MCS004754SCOTB2){ref-type="table"}). OGI519-1068 presented with a milder phenotype than OGI2933-4518, who had a typical *RDH12*-retinal degeneration. This phenotypic difference may be caused by two hypomorphic alleles (p.Arg234His and p.Phe282Val) present in OGI519-1068 and a hypomorphic (p.Arg234His) and a functional null variant (p.Asn147Thr) inherited by OGI2933-4518. Structural and functional studies in bacteria and *Drosophila* ([@MCS004754SCOC7]) have shown that Asn147 is a critical residue in the motif (Asn-Ser-Tyr-Lys) necessary for the coordination of the active site with the water molecule needed for the proton exchange in the reaction. Altering this amino acid resulted in a complete loss of enzymatic activity ([@MCS004754SCOC15]), giving confidence that this is likely a loss-of-function variant. The differences in the phenotypes of these patients can also be due to undiscovered genetic modifiers of the severity of the retinal disease. For example, variants in other genes that code for proteins within the same biochemical pathway as the primary gene may affect expression of disease ([@MCS004754SCOC4]; [@MCS004754SCOC11]). As such, *ABCA4*, coding for a retinal-specific ATP-binding transporter that participates in the visual cycle, is a prime candidate ([@MCS004754SCOC44]). Two patients in our study were found to carry rare variants in *ABCA4*: c.5640T \> A, p.Phe1880Leu (OGI3076-4666) and c.2088T \> G, p.Ile696Met (OGI3077-4669). These were not among the previously reported modifiers, and further studies would need to be undertaken to determine if they have phenotype-modifying effects. Additional polymorphisms in *RDH12* may also act in concert with pathogenic mutations to affect the activity of the underlying protein, thereby altering the phenotype. Two subjects (OGI1611-2841 and OGI3077-4669) were found to be homozygous for the presumed functional null allele c.146T \> C (p.Thr49Met), which may be modified by the p.Arg161Gln polymorphism ([@MCS004754SCOC41]; [@MCS004754SCOC40]). Given this interaction, we searched for additional rare *RDH12*-coding variants and found none present, concluding that these homozygous c.146T \> C (p.Thr49Met) mutations alone were responsible for disease in our patients.

It has been suggested that *RDH12*-associated retinal degeneration has a characteristic and distinguishable phenotype from other retinal disease genes such that sequencing of this locus may be used only to confirm mutations and provide genetic diagnosis ([@MCS004754SCOC38]; [@MCS004754SCOC45]). Although most of our cohort falls within these designations and screening of *RDH12* alone would suffice, three subjects would have been excluded based on macular-prominent phenotypes. For this reason, a more robust approach to clinical diagnosis that is best achieved with targeted panel testing of all known IRD genes as the standard of care is recommended ([@MCS004754SCOC33]; [@MCS004754SCOC10]). *RDH12* mutations can cause a spectrum of retinal degenerations including LCA, CORD, autosomal recessive, autosomal dominant RP, and now macular dystrophy (MD) ([@MCS004754SCOC20]; [@MCS004754SCOC35]; [@MCS004754SCOC16]; [@MCS004754SCOC8]; [@MCS004754SCOC19]). For this reason, we suggest gene-specific nomenclature rather than a phenotypic-based approach that may be misleading due to some retinal diseases overlap with multiple genes. This approach will help drive research into genetic therapeutic strategies while identifying patients who may benefit from therapies.

METHODS {#s4}
=======

Clinical Evaluation {#s4a}
-------------------

Ophthalmic evaluations were performed by clinicians experienced in IRDs. Visual acuity was measured using the Snellen and Early Treatment of Diabetic Retinopathy Study (ETDRS) charts. Kinetic perimetry was performed using a Goldmann perimeter. Full-field ERGs were performed using Burian Allen electrodes and a custom ERG system using previously described parameters at MEE ([@MCS004754SCOC36]; [@MCS004754SCOC30]). Retinal structure was assessed with fundus photography (Topcon Medical Systems; Optos), spectral-domain optical coherence tomography (SD-OCT: Spectralis, Heidelberg Engineering; Cirrus, Carl Zeiss), and fundus autofluorescence (FAF; Spectralis, Heidelberg Engineering; Optos).

Genetic Analysis {#s4b}
----------------

DNA extracted from venous blood using the DNeasy Blood and Tissue Kit (QIAGEN) was used for all the sequencing reactions. All samples were sequenced using the Genetic Eye Disease (GEDi) target capture kit, described previously ([@MCS004754SCOC10]). This capture kit was custom designed to target and enrich exons and select deep intronic regions in more than 260 known IRD genes (Retinal Information Network; <https://sph.uth.edu>) (SureSelect Target Enrichment, Agilent Technologies). Two subjects were sequenced at other facilities (OGI3079-4672 at Prevention Genetics; OGI2356-3915 at the Carver Lab). In addition, WES and data processing were performed by the Genomics Platform at the Broad Institute of MIT and Harvard with an Illumina exome capture (38-Mb target) and sequenced (150-bp paired reads) to cover \>80% of targets at 20× and a mean target coverage of 100×. Exome sequencing data was processed through a pipeline based on Picard and mapping done using the BWA aligner to the human genome build 37 (hg19). Variants were called using GATK HaplotypeCaller package version 3.4 ([@MCS004754SCOC31]). The variant call sets were uploaded to *seqr* (<http://seqr.broadinstitute.org>) and analysis performed using the various inheritance patterns. The NGS data from the GEDi panel was analyzed using Genome Analysis Toolkit (GATK) version 3 ([@MCS004754SCOC31]) and annotated using the Variant Effect Predictor (VEP) tool ([@MCS004754SCOC32]) with additional annotations taken from the Genome Aggregation Database (GnomAD; <https://gnomad.broadinstitute.org>), Genomic Evolutionary Rate Profiling (GERP), SIFT, PolyPhen-2, and retinal expression ([@MCS004754SCOC23]; [@MCS004754SCOC12]; [@MCS004754SCOC1]; [@MCS004754SCOC14]). Sequencing coverage details presented in [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1).

Segregation Analysis {#s4c}
--------------------

Available samples from family members were used for segregation analysis, and in cases in which no family member samples were available, the variants were phased by cloning and Sanger sequencing. Briefly, genomic DNA was amplified from patients using primers flanking the regions including both variants ([Supplemental Table S3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004754/-/DC1)). Amplicons were obtained using Takara-La (Takara Bio USA, Inc.) with cycles of 5 min at 95°C; 30 cycles of 10 sec at 98°C, 8 min at 68°C , with final extension for 10 min at 72°C. All polymerase chain reaction (PCR) was performed on Bio-Rad C1000 Thermocycler (Bio-Rad). PCR-amplified DNA was inserted into the pCR2.1 plasmid, TA cloning kit (Invitrogen) and Sanger sequenced using M13 primers. Sanger sequencing was performed on ABI 3730xl (Applied Biosystems) using BigDye Terminator v3.1 kits (Life Technologies). Sequence analysis was done using SeqManPro (DNAStar; <https://www.dnastar.com/software/molecular-biology/>), in which variants were considered to be in *trans* when they were never present on the same clone.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All variants identified in the present study have been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV001146937--SCV001146952.
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